A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

Part of paid clinical trials in Lake Success, New York.

Sponsor
GlaxoSmithKline
Study ID
NCT07277270
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • GSK5764227 — DRUG
    Participants will receive GSK5764227.
  • Bevacizumab — DRUG
    Participants will receive bevacizumab.
  • Fluorouracil — DRUG
    Participants will receive fluorouracil.
  • leucovorin — DRUG
    Participants will receive leucovorin.
  • Enzalutamide — DRUG
    Participants will receive enzalutamide.

Study Details

The goal of this clinical trial is to test a new medicine called GSK5764227, which delivers a toxin directly to cancer cells to destroy them while sparing healthy cells. The study will combine GSK5764227 with standard treatments to evaluate its safety, examine how the body processes it, check if it triggers any immune responses, and assess whether it can shrink or control cancer.

Key Dates

Start date
Dec 3, 2025
Status verified
Jan 2026
Primary completion
Jul 13, 2026
Completion
Sep 29, 2028

Study Design

Enrollment
84 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Metastatic colorectal cancer (mCRC) cohort A1
  • Experimental: Metastatic colorectal cancer (mCRC) cohort A2
  • Experimental: Metastatic castration-resistant prostate cancer (mCRPC) cohort B

Primary Outcome Measure

Number of participants with adverse events (AEs), Serious AEs (SAEs), AE of special interest (AESIs) and AEs leading to dose modifications [ Time Frame: Up to approximately 31 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
GSK Investigational SiteLake SuccessNew York11042
US GSK Clinical Trials Call Center
[email protected]
877-379-3718
EU GSK Clinical Trials Call Centre
[email protected]
+44 (0) 20 8990 4466
Geraldine O'Sullivan Coyne (PRINCIPAL_INVESTIGATOR)

Find similar trials in Lake Success, NY

By research site
GSK Investigational Site· Lake Success, NY

Related Studies